The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Prognostic tool to identify CAR-T outcomes in patients with aggressive lymphoma
Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, discusses the development of a prognostic tool to identify patients with aggressive non-Hodgkin lymphoma (NHL) who may benefit from CAR-T therapy. The prognosis score used three readily available clinical labs and was found to be able to predict the risk of dying within the first six months of CAR-T therapy with 81% accuracy. This data demonstrates that risk stratification and patient selection are important when it comes to clinical decision making. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
